Zaloguj Zarejestruj się zadarmo

Cotinga Pharmaceuticals organizacji EBITDA

Jaka jest wartość EBITDA organizacji Cotinga Pharmaceuticals?

Wartość EBITDA organizacji Cotinga Pharmaceuticals, Inc. to -CAD$2.14

Jaka jest definicja EBITDA?



EBITDA to zysk firmy przed odliczeniem odsetek, podatków, amortyzacji i jest miarą księgową obliczoną na podstawie zarobków netto firmy, przed odliczeniem kosztów odsetek, podatków, amortyzacji i odliczeniem, jako wskaźnika bieżącej rentowności operacyjnej spółki.

Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.

EBITDA firm w Health Care sektor na TSXV w porównaniu do Cotinga Pharmaceuticals

Czym się zajmuję organizacja Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Firmy z ebitda podobne do Cotinga Pharmaceuticals